MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy

被引：25

作者：

Umerez, Maitane ^{[1
]}

Gutierrez-Camino, Angela ^{[1
]}

Munoz-Maldonado, Carmen ^{[1
]}

Martin-Guerrero, Idoia ^{[1
]}

Garcia-Orad, Africa ^{[1
,2
]}

机构：

[1] Univ Basque Country, Fac Med & Nursery, Dept Genet Phys Anthropol & Anim Physiol, UPV EHU,Barrio Sarriena S-N, Leioa, Spain

[2] BioCruces Hlth Res Inst, Baracaldo, Spain

来源：

PHARMACOGENOMICS & PERSONALIZED MEDICINE | 2017年 / 10卷

关键词：

MTHFR; methotrexate; toxicity; outcome; C677T; A1298C; METHYLENETETRAHYDROFOLATE REDUCTASE C677T; GENETIC POLYMORPHISMS; TURKISH CHILDREN; CANDIDATE GENES; RISK-FACTORS; TOXICITY; PHARMACOGENETICS; ASSOCIATION; PREDICTION; PROGNOSIS;

D O I：

10.2147/PGPM.S107047

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Methotrexate (MTX) is an important component in the therapy used to treat childhood acute lymphoblastic leukemia ( ALL). Methylenetetrahydrofolate reductase ( MTHFR) is a key enzyme for MTX pharmacokinetics. Two single-nucleotide polymorphisms in MTHFR gene, C677T and A1298C, affecting MTHFR activity, have been widely studied as potential markers of MTX toxicity and/or outcome in pediatric ALL. In this review, we show that the majority of published reports do not find association or present opposite effect. Therefore, MTHFR C677T and A1298C polymorphisms do not seem to be good markers of MTX-related toxicity and/or outcome in pediatric ALL. The efforts should be focused on other genes, such as transporter genes or microRNA-related genes.

引用

页码：69 / 78

页数：10

共 50 条

[11] RATIONAL USE OF METHOTREXATE IN MAINTENANCE THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
王志宏
于载泺
CHINESEMEDICALJOURNAL, 1992, (02)
[12] RATIONAL USE OF METHOTREXATE IN MAINTENANCE THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
王志宏
于载泺
中华医学杂志(英文版), 1992, (02) : 147 - 152
[13] Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) sensitivity of childhood B-precursor acute lymphoblastic leukemia (BP-ALL).
Taub, JW
Kaspers, GJL
Rots, MG
Van Zantwijk, CH
Matherly, LH
Ravindranath, Y
BLOOD, 2000, 96 (11) : 100A - 100A
[14] Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methotrexate (MTX) sensitivity of childhood B-precursor acute lymphoblastic leukemia (BP-ALL).
Ravindranath, Y
Kaspers, GJL
Rots, MG
Van Zantwijk, CH
Taub, JW
Matherly, LH
LEUKEMIA, 2001, 15 (03) : 496 - 496
[15] Influence of MTHFR and RFC1 Polymorphisms on Toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma
Shimasaki, Noriko
Mori, Tetyuya
Torii, Chiharu
Sato, Reiko
Shimada, Hiroyuki
Tanigatvara, Yusuke
Kosaki, Kenjiro
Takahashi, Takao
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (05) : 347 - 352
[16] Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia
Krajinovic, M
Lemieux-Blanchard, É
Chiasson, S
Primeau, M
Costea, I
Moghrabi, A
PHARMACOGENOMICS JOURNAL, 2004, 4 (01): : 66 - 72
[17] Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia
M Krajinovic
É Lemieux-Blanchard
S Chiasson
M Primeau
I Costea
A Moghrabi
The Pharmacogenomics Journal, 2004, 4 : 66 - 72
[18] Effect of the RS1801131 of MTHFR on Methotrexate-Related Toxicity in Childhood Acute Lymphoblastic Leukemia
Frikha, R.
PEDIATRIC BLOOD & CANCER, 2020, 67 : S406 - S407
[19] METHOTREXATE POLYGLUTAMATES DURING INTERVAL THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
de Beaumais, Adam T.
Fakhoury, M.
Medard, Y.
Zhang, D.
Yakouben, K.
Dervieux, T.
Jacqz-Aigrain, E.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 130 - 130
[20] METHOTREXATE POLYGLUTAMATES DURING INTERVAL THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA TREATMENT
De Beaumais, T. Adam
Fakhoury, M.
Medard, Y.
Zhang, D.
Yakouben, K.
Dervieux, T.
Jacqz-Aigran, E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S51 - S51

← 1 2 3 4 5 →